Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.70 |
| ▸ | TGM2 | P21980 | 1/20 | 0.67 |
| ▸ | IMPDH2 | P12268 | 7/20 | 0.64 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.64 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.64 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.64 |
| ▸ | KRAS | P01116 | 6/20 | 0.61 |
| ▸ | GSK3A | P49840 | 2/20 | 0.61 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.61 |
| ▸ | HINT1 | P49773 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E626 SCHEMBL6534995 | 0.92 | NT5E (0.60) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL18763818 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL21803790 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL18785103 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL13497991 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL9980018 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL20677331 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL21163348 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL18759049 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL20276926 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116036278-A | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| CN-110799245-B | Compositions and methods for treating cancer with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2022-08-09 | — | — | CN | claimed |
| EP-3310384-A1 | VACCINE COMPOSITION | CureVac AG (DE) | 2018-04-25 | — | — | EP | claimed |
| WO-2016203025-A1 | VACCINE COMPOSITION | CUREVAC AG (DE) | 2016-12-22 | — | — | WO | claimed |
| CN-118339176-A | Engineered myocardial composition | 博德研究所 | 2024-07-12 | — | — | CN | disclosed |
| CN-118265520-A | Shear thinning composition for ablation | 波士顿科学国际有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240189410-A1 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIOIDES (CLOSTRIDIUM) DIFFICILE | PFIZER (US) | 2024-06-13 | — | — | US | disclosed |
| CN-114929659-B | Co-crystals of pterostilbene and compositions containing same | 晶体工程智能研究中心公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118076743-A | Engineered muscle targeting compositions | 博德研究所 | 2024-05-24 | — | — | CN | disclosed |
| CN-117561064-A | Diagnosis and treatment of cancer using c-Met inhibitors | 冠科美博有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-110719920-B | Protein heterodimers and uses thereof | 苏州丁孚靶点生物技术有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117377485-A | Safer vaccine | 王慧茹 | 2024-01-09 | — | — | CN | disclosed |
| CN-105517542-B9 | Cytotoxic T cell response modulators | 德国癌症研究中心 | 2022-01-11 | — | — | CN | disclosed |
| CN-105517542-B | Cytotoxic T cell response modulators | 德国癌症研究中心 | 2021-12-07 | — | — | CN | disclosed |
| CN-112912127-A | Tethered ultrasound devices and uses thereof | 索诺生物股份有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-111954524-A | Application of colchicine in inhibiting tumor growth and metastasis | 默里和普尔企业有限公司 | 2020-11-17 | — | — | CN | disclosed |
| CN-111295448-A | Lipid nanoparticle formulation of non-viral capsid-free DNA vectors | 世代生物公司 | 2020-06-16 | — | — | CN | disclosed |
| US-20180296663-A1 | VACCINE COMPOSITION | CUREVAC AG (DE) | 2018-10-18 | — | — | US | disclosed |
| EP-3310384-A1 | VACCINE COMPOSITION | CureVac AG (DE) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016203025-A1 | VACCINE COMPOSITION | CUREVAC AG (DE) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296663-A1 | VACCINE COMPOSITION | STING1, MYD88, TLR9 | NT5E 3050/4885TGM2 2146/4885IMPDH2 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.